⚡️🇺🇸#YETI #отчетность
YETI Reports Second Quarter 2021 Results
Q2 Non-GAAP EPS of $0.68 beats by $0.12;
GAAP EPS of $0.63 beats by $0.11.
Revenue of $357.67M (+44.8% Y/Y) beats by $29.15M.
Gross margin increased 390 bps to 58.5%.
Gross profit increased 54% to $354.3M
#прогноз FY 2021 Guidance: Net sales are now expected to increase between 26% and 28% vs. consensus of $23.02%; Adjusted operating income as a percentage of net sales is expected to be approximately 20.5%,GAAP EPS is now expected to be between $2.25 and $2.29; and Non-GAAP EPS is expected to be between $2.42 and $2.46 vs.
YETI Reports Second Quarter 2021 Results
Q2 Non-GAAP EPS of $0.68 beats by $0.12;
GAAP EPS of $0.63 beats by $0.11.
Revenue of $357.67M (+44.8% Y/Y) beats by $29.15M.
Gross margin increased 390 bps to 58.5%.
Gross profit increased 54% to $354.3M
#прогноз FY 2021 Guidance: Net sales are now expected to increase between 26% and 28% vs. consensus of $23.02%; Adjusted operating income as a percentage of net sales is expected to be approximately 20.5%,GAAP EPS is now expected to be between $2.25 and $2.29; and Non-GAAP EPS is expected to be between $2.42 and $2.46 vs.
⚡️💥🇺🇸#REGN
Regeneron Pharma: Phase 3 Trial of Libtayo(R) (cemiplimab-Rwlc) Combined With Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients With First-line Advanced Non-small Cell Lung Cancer
Regeneron Pharma: Phase 3 Trial of Libtayo(R) (cemiplimab-Rwlc) Combined With Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients With First-line Advanced Non-small Cell Lung Cancer
💥🇺🇸#PANW
Palo Alto Networks - парнерство с Envision Virgin Racing
Envision Virgin Racing and Palo Alto Networks Announce Multiyear Partnership
Palo Alto Networks - парнерство с Envision Virgin Racing
Envision Virgin Racing and Palo Alto Networks Announce Multiyear Partnership
⚡️💥🇪🇺#SNY
Sanofi: Trial Of Libtayo Combined W/Chemotherapy Stopped Early
Cites Significant Improvement In Overall Survival
Sanofi: Trial Of Libtayo Combined W/Chemotherapy Stopped Early
Cites Significant Improvement In Overall Survival
🇺🇸#AAPL
Apple начинает продвигать собственные услуги с эксклюзивных предложений для клиентов Apple Card
Apple now promoting its services with ‘exclusive offers’ for Apple Card users
Apple начинает продвигать собственные услуги с эксклюзивных предложений для клиентов Apple Card
Apple now promoting its services with ‘exclusive offers’ for Apple Card users
This media is not supported in your browser
VIEW IN TELEGRAM
⚡️🇺🇸#MRNA #отчетность
Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
Revenue: USD4.35B (est USD4.27B)
EPS: USD6.46 (est USD5.82)
Covid Vaccine Revenue: USD4.2B (est USD4.09B)
💥Covid Shot 93% Effective 6 Months After Second Dose
Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
Revenue: USD4.35B (est USD4.27B)
EPS: USD6.46 (est USD5.82)
Covid Vaccine Revenue: USD4.2B (est USD4.09B)
💥Covid Shot 93% Effective 6 Months After Second Dose
⚡️🇺🇸#REGN #отчетность
Regeneron Reports Second Quarter 2021 Financial and Operating Results
Revenue: USD5.14B (est USD4.00B)
Adj EPS: USD25.80 (est USD17.16)
Regeneron Reports Second Quarter 2021 Financial and Operating Results
Revenue: USD5.14B (est USD4.00B)
Adj EPS: USD25.80 (est USD17.16)
⚡️💥🇺🇸#ORMP
Oravax to Present Keynote Talk on Oral COVID-19 Vaccine at the Arena Intl Vaccines Virtual Conference 2021
Oravax to Present Keynote Talk on Oral COVID-19 Vaccine at the Arena Intl Vaccines Virtual Conference 2021
This media is not supported in your browser
VIEW IN TELEGRAM
⚡️💥🇺🇸#MRK
Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial
Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial
💥☢️#XMOON #крипто #Reddit
монета Reddit-ов r/CryptoCurrency Moons порвала всех после того, как разработчики проекта объявили о новой масштабируемой сети, которая обеспечит более быстрые и эффективные транзакции. Проект может быть развернут в основной сети Ethereum #ETH с помощью решения уровня 2 Arbitrum.
———————————————-
📲Скачайте приложение BYBIT (iOS или Android), чтобы наслаждаться криптотрейдингом, где удобно. Общайтесь с трейдерами в в телеграм комьюнити Bybit
монета Reddit-ов r/CryptoCurrency Moons порвала всех после того, как разработчики проекта объявили о новой масштабируемой сети, которая обеспечит более быстрые и эффективные транзакции. Проект может быть развернут в основной сети Ethereum #ETH с помощью решения уровня 2 Arbitrum.
———————————————-
📲Скачайте приложение BYBIT (iOS или Android), чтобы наслаждаться криптотрейдингом, где удобно. Общайтесь с трейдерами в в телеграм комьюнити Bybit
⚠️🌎#вакцинация #мир #вакцина #warning #вирус #мутация #пандемия
Moderna считает, что дельта штамм может привести к увеличению числа заражений у вакцинированных - презентация
MODERNA MRNA.O SAYS BELIEVE THAT DELTA VARIANT, SEASONAL EFFECTS WILL LEAD TO AN INCEASE OF BREAKTHROUGH INFECTIONS IN VACCINATED INDIVIDUALS-SLIDES
——————————-
Эффективность существующих вакцин против COVID-19 снижается в связи с распространением дельта-штамма - BBG со ссылкой на исследование британских ученых - подробнее
Moderna считает, что дельта штамм может привести к увеличению числа заражений у вакцинированных - презентация
MODERNA MRNA.O SAYS BELIEVE THAT DELTA VARIANT, SEASONAL EFFECTS WILL LEAD TO AN INCEASE OF BREAKTHROUGH INFECTIONS IN VACCINATED INDIVIDUALS-SLIDES
——————————-
Эффективность существующих вакцин против COVID-19 снижается в связи с распространением дельта-штамма - BBG со ссылкой на исследование британских ученых - подробнее
⚡️⚠️🇨🇳#китай #ограничения #кино
Китай вводит ограничение в кинотеатрах из-за ковида
CHINA FILM ADMINISTRATION SAYS CAPS CINEMA CAPACITY AT 75% FOR LOW-RISK AREAS, SUSPENDS OPERATION OF CINEMAS IN HIGH AND MEDIUM-RISK AREAS
Китай вводит ограничение в кинотеатрах из-за ковида
CHINA FILM ADMINISTRATION SAYS CAPS CINEMA CAPACITY AT 75% FOR LOW-RISK AREAS, SUSPENDS OPERATION OF CINEMAS IN HIGH AND MEDIUM-RISK AREAS